Phase 2 Inovio COVID-19 Vaccine
Phase 2/3 study of INO-4800 DNA vaccine for SARS-CoV-2 to assess safety, efficacy & immunogenicity of vaccine in health volunteers at high risk for SARS-CoV-2 exposure. INO-4800 1.0mg or placebo given by intradermal injection followed by electroporation using CELLECTRA2000 investigational device at Day 0 and Day 28. Procedures include physicals, biospecimen collection and subject diaries over 8 outpatient visits plus phone calls.
If you agree to join the study, you will be asked to complete the following research procedures:
- Study Identifier: 843500